Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)
3.610
+0.040 (1.12%)
At close: Feb 3, 2026
SHE:300026 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,464 | 5,757 | 6,025 | 6,603 | 7,656 | 6,463 |
Other Revenue | 26.24 | 26.24 | 84.31 | 47.44 | 14.63 | 25.37 |
| 5,490 | 5,783 | 6,109 | 6,650 | 7,671 | 6,488 | |
Revenue Growth (YoY) | -2.44% | -5.34% | -8.14% | -13.30% | 18.22% | 29.69% |
Cost of Revenue | 2,654 | 2,793 | 2,827 | 2,826 | 3,267 | 2,858 |
Gross Profit | 2,836 | 2,989 | 3,282 | 3,824 | 4,403 | 3,630 |
Selling, General & Admin | 2,418 | 2,534 | 2,463 | 2,751 | 3,054 | 2,648 |
Research & Development | 202.07 | 223.45 | 209.81 | 230.85 | 196.59 | 177.03 |
Other Operating Expenses | 54.4 | 48.74 | 41.4 | 61.72 | 76.44 | 1.87 |
Operating Expenses | 2,751 | 2,887 | 2,767 | 3,100 | 3,401 | 2,896 |
Operating Income | 85.46 | 102.42 | 515.52 | 724.42 | 1,002 | 733.98 |
Interest Expense | -19.17 | -44.86 | -61.57 | -69.67 | -50.1 | -30.07 |
Interest & Investment Income | 11.78 | 17.31 | 19.31 | 14.18 | 11.38 | 12.03 |
Currency Exchange Gain (Loss) | 3.92 | 3.92 | 2.41 | 17.62 | -6.34 | -29.34 |
Other Non Operating Income (Expenses) | -48.14 | -22.2 | -18.49 | -35.65 | -26.86 | 21.11 |
EBT Excluding Unusual Items | 33.84 | 56.59 | 457.19 | 650.91 | 930.58 | 707.71 |
Impairment of Goodwill | -17.34 | -17.34 | -23.52 | - | -58.18 | - |
Gain (Loss) on Sale of Investments | -7.4 | -5.63 | -1.4 | - | -22.98 | - |
Gain (Loss) on Sale of Assets | 1.24 | 1.08 | 1.06 | 0.01 | -2.87 | 0.03 |
Asset Writedown | -66.68 | -30.33 | -4.05 | -2.36 | -9.35 | -24.3 |
Other Unusual Items | 49.62 | 49.62 | 177.54 | 67.82 | 16.99 | -0.03 |
Pretax Income | -6.73 | 53.98 | 606.82 | 716.37 | 854.18 | 683.41 |
Income Tax Expense | 70.79 | 31.04 | 105.25 | 95.14 | 183.32 | 123.73 |
Earnings From Continuing Operations | -77.52 | 22.95 | 501.57 | 621.23 | 670.85 | 559.68 |
Minority Interest in Earnings | 11.4 | -1.48 | 5.06 | 3.01 | 16.47 | 13.71 |
Net Income | -66.13 | 21.47 | 506.63 | 624.24 | 687.32 | 573.39 |
Net Income to Common | -66.13 | 21.47 | 506.63 | 624.24 | 687.32 | 573.39 |
Net Income Growth | - | -95.76% | -18.84% | -9.18% | 19.87% | 42.45% |
Shares Outstanding (Basic) | 2,061 | 2,147 | 2,980 | 2,973 | 2,988 | 3,018 |
Shares Outstanding (Diluted) | 2,061 | 2,147 | 2,980 | 2,973 | 2,988 | 3,018 |
Shares Change (YoY) | -27.37% | -27.97% | 0.26% | -0.53% | -0.98% | 4.96% |
EPS (Basic) | -0.03 | 0.01 | 0.17 | 0.21 | 0.23 | 0.19 |
EPS (Diluted) | -0.03 | 0.01 | 0.17 | 0.21 | 0.23 | 0.19 |
EPS Growth | - | -94.12% | -19.05% | -8.70% | 21.05% | 35.71% |
Free Cash Flow | 705.19 | 659.12 | 1,183 | -24.93 | -285.85 | -367.12 |
Free Cash Flow Per Share | 0.34 | 0.31 | 0.40 | -0.01 | -0.10 | -0.12 |
Dividend Per Share | 0.030 | 0.030 | 0.030 | 0.030 | 0.040 | 0.040 |
Dividend Growth | - | - | - | -25.00% | - | -20.00% |
Gross Margin | 51.65% | 51.69% | 53.73% | 57.50% | 57.40% | 55.95% |
Operating Margin | 1.56% | 1.77% | 8.44% | 10.89% | 13.07% | 11.31% |
Profit Margin | -1.20% | 0.37% | 8.29% | 9.39% | 8.96% | 8.84% |
Free Cash Flow Margin | 12.84% | 11.40% | 19.36% | -0.38% | -3.73% | -5.66% |
EBITDA | 364.62 | 387.15 | 807.69 | 974.09 | 1,217 | 923.97 |
EBITDA Margin | 6.64% | 6.69% | 13.22% | 14.65% | 15.86% | 14.24% |
D&A For EBITDA | 279.16 | 284.74 | 292.17 | 249.67 | 214.2 | 189.99 |
EBIT | 85.46 | 102.42 | 515.52 | 724.42 | 1,002 | 733.98 |
EBIT Margin | 1.56% | 1.77% | 8.44% | 10.89% | 13.07% | 11.31% |
Effective Tax Rate | - | 57.49% | 17.34% | 13.28% | 21.46% | 18.11% |
Revenue as Reported | 5,490 | 5,783 | 6,109 | 6,650 | 7,671 | 6,488 |
Advertising Expenses | - | 8.6 | 9.15 | 12.6 | 21.21 | 19.45 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.